Avalo Therapeutics, Inc. (AVTX)
Develops antibody drugs targeting inflammation to treat immune diseases.
$19.32-0.01%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+144.9%
The outlook
AVTX trades at $19.32, sitting well above its 50- and 200-day moving averages with strong upward momentum in its recent trend. Analyst consensus is strongly bullish, with an average price target implying substantial gains versus the current level. The stock is positioned in the upper half of its 52-week range.
What’s behind the score
Analyst consensusStrong Buy — 1.1 avg of 13 analysts
Price trendAbove its 50- & 200-day averages
52-week range73% of the way from its 52-week low to high
Price targetAvg target +131% vs current price
Analyst price target
~12-month · 13 analysts$44.69average target+131.3% vs now
Now $19.32
Low $34.00High $60.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$1.02B
52-wk high
$24.27
52-wk low
$6.21
50-day avg
$16.87
200-day avg
$16.42
Trailing P/E
—